Pharmaceutical Technology

JULY 3, 2025

Dizal has received US Food and Drug Administration (FDA) approval for Zegfrovy (sunvozertinib) to treat adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), following progression on or after receiving platinum-based chemotherapy.

Packaging

Express Pharma

JUNE 12, 2025

Historically, the management of metastatic cancer has relied on four primary therapeutic modalities: surgery, radiation therapy, chemotherapy, and, more recently, immunotherapy, The 2018 Nobel Prize in Physiology or Medicine was awarded to Tasuku Honjo and James Allison for their discoveries in cancer immunology.

Chemotherapy

STAT

JUNE 26, 2025

… Vital chemotherapy drugs used around the world have failed quality tests, putting cancer patients in more than 100 countries at risk of ineffective treatments and potentially fatal side effects, an investigation by  The Bureau of Investigative Journalism  (TBIJ) reveals. And of course, do keep in touch.

Drug Pricing

STAT

JUNE 26, 2025

The drug, called pemvidutide, failed to show a statistically significant improvement in liver fibrosis compared to a placebo. 

Chemotherapy

STAT

OCTOBER 28, 2022

 Over the past week, Areva Pharmaceuticals began marketing vials of fludarabine at a wholesale price of $2,736, much more than the $272 charged for the same dosage by Fresenius Kabi and the $109 price from Teva Pharmaceuticals. Continue to STAT+ to read the full story…

Drug Pricing

STAT

JULY 28, 2023

WASHINGTON — House Republicans have drafted drug-shortage legislation that differs significantly from the approach Democrats propose to stem shortages of chemotherapies and other critical medicines that hospitals typically use.

Drug Pricing

STAT

SEPTEMBER 14, 2023

WASHINGTON — A nonprofit formed by hospitals to deal with drug shortages is considering a move into chemotherapies. Frustrated by drug shortages and the price spikes that typically ensue, executives from large hospital systems launched the nonprofit Civica Rx to deal with the problem in September 2018.

Hospitals

STAT

FEBRUARY 14, 2024

Three group purchasing organizations, or GPOs, buy drugs on behalf of most hospitals in the U.S., The move comes amid growing anxiety over shortages of numerous medicines — from chemotherapies to antibiotics — in recent years.

Nursing Homes

STAT

JUNE 28, 2023

“Oftentimes we can cure kids of their disease, but we can’t do that without the drugs,” said Unguru, a pediatric hematologist oncologist at Children’s Hospital at Sinai in Baltimore and the Johns Hopkins School of Medicine. “It’s just so, so maddening.”

Chemotherapy

STAT

JULY 31, 2023

… House Republicans have drafted drug-shortage legislation that differs significantly from the approach Democrats propose to stem shortages of chemotherapies and other critical medicines that hospitals typically use , STAT explains. Republicans

Drug Pricing

pharmaphorum

JULY 16, 2021

The rejection leaves men in England and Wales newly-diagnosed with prostate cancer with three options: hormone therapy on its own, or alongside either Pfizer’s Xtandi (enzalutamide) – recently approved by NICE – or docetaxel chemotherapy.

Chemotherapy

Big Molecule Watch

JANUARY 10, 2025

To close out the year, the FDA also approved on an accelerated basis Jazz Pharmaceuticalss ZIIHERA (zanidatamab-hrii), the first and only dual HER2-targeted bispecific antibody and chemotherapy-free treatment for patients living with biliary tract cancer; Merus N.V.s

Biosimilars

STAT

SEPTEMBER 12, 2023

WASHINGTON — The White House says it’s working to end shortages of three key generic chemotherapies. Carboplatin, cisplatin, and methotrexate are three of 15 cancer drugs in shortage in the United States.

Chemotherapy

STAT

AUGUST 15, 2023

An example: Cancer patients are likely dying as a result of drug shortages that occurred partly because generic chemotherapies have been allowed to become too cheap. American medicine is a tragic paradox.

Chemotherapy

pharmaphorum

SEPTEMBER 8, 2020

In England for instance, the introduction of a biosimilar to prevent neutropenia in patients undergoing chemotherapy, resulted in a number of Strategic Health Authorities reassessing their guidance relating to this medicine. 6 Forbes, ‘Biologic Medicines: The Biggest Driver of Rising Drug Prices’. Published 17 September 2018.

Biosimilars

Pharmaceutical Technology

JULY 8, 2025

Go deeper with GlobalData Reports LOA and PTSR Model - Efbemalenograstim Alfa La in Chemotherapy Indu. Nominate Now Share Copy Link Share on X Share on Linkedin Share on Facebook Go deeper with GlobalData Reports LOA and PTSR Model - Efbemalenograstim Alfa La in Chemotherapy Indu. How will RFK Jr’s American dream for vaccines play out?

Packaging

BioPharma Dive

JULY 8, 2025

Both are developing treatments that draw on the idea of antibody-drug conjugates, but swap out the chemotherapy toxin for a protein degrader. You can unsubscribe at anytime. Other targeted protein degradation companies are trying out new degrader technologies, among them Nurix Therapeutics and Orum Therapeutics.

Immunization

STAT

JANUARY 21, 2025

We learn more about the scope of effect of GLP-1s, and see a new antibody-drug conjugate approved. Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Another day, another president. Good morning!

Chemotherapy